Macrogen Leads Precision Medicine by Advancing the Realization of the "$100 Genome Age"

  Macrogen Leads Precision Medicine by Advancing the Realization of the "$100
  Genome Age"

- Completed the Installation of NovaSeq 6000, the Latest Genome Analysis
Equipment by Illumina
- Capacity for Genome Analysis Service Doubled and Capable of Analyzing More
Than 70,000 People Per Year
- Leads Precision Medicine by Advancing the Realization of “the $100 Genome
Age”

Business Wire

SEOUL, South Korea -- March 28, 2017

Macrogen Inc. (CEO Hyun-yong Jeong, www.macrogen.com) (KOSDAQ:038290), a
precision medicine biotechnology company, announced on March 28 that it
completed the installation of the NovaSeq 6000, the latest equipment for
genetic analysis by Illumina Inc., on the network of the Macrogen Global
Genome Center.

The NovaSeq 6000 is a sequencing system Illumina introduced at the JP Morgan
Healthcare Conference last January, foretelling the “$100 Genome Age.” This
high-tech equipment, a new platform for genome sequence analysis based on
next-generation sequencing (NGS), is known to be able to analyze a maximum of
6 terabases or 60 whole genome sequencings within 2 days, which means it is
five times faster than the former equipment HiSeq X(for one unit) in terms of
data processing speed.

As a leader in the genetic analysis industry, Macrogen, which has been
utilizing the latest analysis technologies before others and providing them
for the market, employed the NovaSeq 6000 by Illumina ahead of others,
installed one in its U.S. branch office and another one in the head office in
Korea on March 27, and is planning to have one more within the third quarter.

Global services using the newly installed NovaSeq 6000 will begin in earnest
in April after a test run. Counseling and ordering for sequencing services
based on the NovaSeq 6000 will be available upon request and analysis results
will be provided from early April.

With this investment, Macrogen’s capacity for genome analysis services will
double and the company is expected to be able to analyze more than 8,000
terabases or 70 thousand genomes, which is equal to the top domestic companies
and fifth in the world market.

“With the release of the NovaSeq 6000 by Illumina, expectations for the ‘$100
Genome Age’ are high. Although it will take some time before the expectations
are realized, there is no doubt that Macrogen, which has realized the ‘$1,000
Genome Age,’ will also lead the ‘$100 Genome Age,’” Macrogen CEO Hyun-yong
Jeong said.

He added, “As the cost for genome analysis goes down, research on the
relationship between genes and diseases will be vitalized and the information
from them will be very useful for hospitals. Macrogen will advance the
realization of the ‘$100 Genome Age’ and take the initiative in the precision
medicine sector.”

Macrogen has kept investing and researching in this area to expand into the
clinical diagnosis and consumer markets on the basis of global technological
leadership in the field of gene and genome analysis. As a result, the company
launched not only Faest^TM, a next-generation antenatal genome examination
service, as well as other services in obstetrics, gynecology and pediatrics,
but also the SHARP3^TM service with the official permit of direct-to-consumer
genetic analysis. In addition, Macrogen put a lot of efforts into the
development of a genetic examination panel service for cancer and is about to
release it in the global market this year. In the domestic market in
particular, Macrogen will open its services in line with the arrangement of
related systems such as having the services covered by the health insurance
system, and maximize the effect of its collaborative network for precision
medicine with Bundang Seoul National University Hospital and National Cancer
Center.

[Contact Us for Services]
Korea: Macrogen Inc., ngs@macrogen.com
Europe: Macrogen Corp. EUROPE, ngs@macrogen-europe.com
America: Macrogen Corp., ngssales@macrogenlab.com
Japan: Macrogen Japan Corp., ngs@macrogen-japan.co.jp

View source version on businesswire.com:
http://www.businesswire.com/news/home/20170328005622/en/

Contact:

[Contact Us for the Press Release]
Macrogen Inc.
Mikyung Kim, +82-2-2113-7029
Senior Manager
Management Innovation Dept.
chloe@macrogen.com
Press spacebar to pause and continue. Press esc to stop.